These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18572032)

  • 21. Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program.
    Ryan J; Linde-Zwirble W; Engelhart L; Cooper L; Cohen DJ
    Circulation; 2009 Feb; 119(7):952-61. PubMed ID: 19204307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are drug-eluting stents safe?: Definitely! Or probably... possibly? Or maybe not yet...
    Nakazawa G; Ladich E; Virmani R
    Clin Pharmacol Ther; 2009 Aug; 86(2):127-30. PubMed ID: 19621005
    [No Abstract]   [Full Text] [Related]  

  • 23. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the landscape of stent thrombosis: the drug-eluting versus bare-metal stent controversy.
    Rizik DG; Klassen KJ
    Am J Cardiol; 2008 Nov; 102(9 Suppl):4J-11J. PubMed ID: 18928786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of bifurcation lesions using dedicated bifurcation stents versus classic bare-metal stents. Randomized, controlled trial with 12-month angiographic follow up.
    Cervinka P; Bystron M; Spacek R; Kvasnak M; Adhikari S; Jakabcin J
    J Invasive Cardiol; 2008 Oct; 20(10):516-20. PubMed ID: 18829995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do the benefits outweigh the risks with drug-eluting stents?
    Kløw NE
    Scand Cardiovasc J; 2007 Jan; 41(1):8-9. PubMed ID: 17365970
    [No Abstract]   [Full Text] [Related]  

  • 27. Platelet activation and stent thrombosis.
    Georgiadou P; Voudris V
    Hellenic J Cardiol; 2017; 58(1):49-50. PubMed ID: 28396052
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries.
    Bonello L; De Labriolle A; Lemesle G; Roy P; Steinberg DH; Slottow TL; Xue Z; Torguson R; Kaneshige K; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):496-500. PubMed ID: 19195509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome.
    Trenk D; Neumann FJ
    Eur J Clin Pharmacol; 2008 Mar; 64(3):227-32. PubMed ID: 18075736
    [No Abstract]   [Full Text] [Related]  

  • 30. Late outcomes after drug-eluting stent implantation in "real-world" clinical practice.
    Ramsdale DR; Rao A; Asghar O; Ramsdale KA; McKay E
    J Invasive Cardiol; 2008 Oct; 20(10):493-500. PubMed ID: 18829991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Off-label use of stents: bare-metal versus drug-eluting stents.
    Girod JP; Mulukutla SR; Marroquin OC
    Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1095-106. PubMed ID: 18793112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjunctive Pharmacotherapy Part II.
    Kereiakes DJ
    J Invasive Cardiol; 2009 Apr; 21(4):A6, A9. PubMed ID: 19353826
    [No Abstract]   [Full Text] [Related]  

  • 33. Status of drug-eluting coronary stents.
    Chodosh A; Korr KS; Burtt D
    Med Health R I; 2008 Oct; 91(10):309-12, 314. PubMed ID: 19044106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-eluting stent thrombosis.
    Stähli BE; Camici GG; Tanner FC
    Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):45-52. PubMed ID: 19124388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety?
    Finn AV; Nakazawa G; Kolodgie F; Virmani R
    Eur Heart J; 2009 Aug; 30(15):1828-30. PubMed ID: 19515688
    [No Abstract]   [Full Text] [Related]  

  • 36. Novel antiplatelet therapies following percutaneous coronary interventions.
    Ahrens I; Bode C
    Curr Opin Investig Drugs; 2009 Sep; 10(9):902-11. PubMed ID: 19705332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is it time to take bare metal stents off the catheter laboratory shelf?
    Kassimis G; Banning AP
    Eur Heart J; 2016 Dec; 37(45):3372-3375. PubMed ID: 27282614
    [No Abstract]   [Full Text] [Related]  

  • 38. The high cost of nonadherence after percutaneous coronary intervention--can health care reform solve this problem?
    Mukherjee D
    Am Heart J; 2009 Oct; 158(4):506-8. PubMed ID: 19781406
    [No Abstract]   [Full Text] [Related]  

  • 39. Stent thrombosis after percutaneous coronary intervention for bifurcation lesions.
    Tan HC
    J Interv Cardiol; 2009 Apr; 22(2):114-6. PubMed ID: 19379468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.